Nanoconstructs Core

纳米结构核心将（1）开发新的纳米结构，可以与目前在CCNE中使用的纳米颗粒并排比较，（2）扩大现有的纳米颗粒制剂，使其可以广泛分布。其基本原理是，目前正在测试纳米颗粒，主要是因为它们是可用的;然而，目前还不清楚哪种纳米颗粒最适合特定的应用，或者如何设计它们以实现最高的功效。因此，一个同时专注于设计和测试新结构的核心将大大加快每个CCNE研究项目的进展。因此，研究人员可以在其早期开发中充分利用纳米结构，这将促进这一科学应用于临床阶段。 这个核心的基础设施代表了一种新的范式和模型，用于如何开发和快速测试纳米结构。我们设计了一个阶段门控过程，新的构建体有可能超过当前构建体的能力，因为它们同时针对相同的癌症进行比较。早期阶段的比较将通过CCNE试点项目的反馈来促进，随着最有效的药剂被确定、缩放和分配，资源将以动态的方式分配。Nanoconstructs Core将在治疗，诊断和成像标准化方面发挥关键作用，因为它将作为CCNE开发的纳米结构的测试床和信息交换所的资源。一个可以提供质量受控、高度均匀的纳米粒子探针的单一来源将促进并实现所有CCNE项目的更好整合，这将确保改善纳米癌症研究的联系，并加快纳米技术在癌症临床治疗中的使用。因此，核心将以反馈和前馈的方式与项目密切合作，并将有助于发展一个拥有纳米级合成和制造以及与生物相关分子结合的纳米材料表征专业知识的当地社区。

The Nanoconstructs Core will (1) develop new nanoconstructs that can be compared side-by-side with nanoparticles currently used in the CCNE and (2) scale-up existing preparations of nanoparticles so that they can be widely distributed. The rationale is that nanoparticles are currently being tested primarily because they are available; however, it is still not obvious which nanoparticles are best-suited for a particular application or how to design them to achieve the highest efficacy. Therefore, a Core focused simultaneously on designing and testing new constructs will greatly accelerate progress in each of the CCNE research projects. Thus, researchers can take full advantage of the nanoconstructs in their eariy development, which will facilitate the application of this science into clinical stages. The infrastructure of this Core represents a new paradigm and model for how nanoconstructs should be developed and rapidly tested. We have designed a stage gating process where the new constructs have the potential to surpass the capabilities of the current ones because they are being compared at the same time against the same cancers. Comparison at the eariy stages will be facilitated by feedback from CCNE pilot projects, and resources will be allocated in a dynamic manner as the most efficacious agents are identified, scaled, and distributed. The Nanoconstructs Core will play a critical role in standardizing agents for therapeutics, diagnostics, and imaging because it will serve as a resource for test-bedding and a clearinghouse for CCNE-developed nanoconstructs. A single source that can provide quality-controlled, highly uniform nanoparticle probes will promote and enable better integration across all CCNE projects¿which will ensure improved nano-cancer research connections as well as expedite the use of nanotechnology in clinical treatments of cancer. Hence, the Core will work closely with the projects in a feed-back and feed-forward manner and will also serve to nucleate the development of a local community with expertise in nanoscale synthesis and fabrication and characterization of nanomaterials coupled to biologically relevant molecules.